Good evening :)
$
₹
Charles River Laboratories

Charles River Laboratories

CRL

NYSE
Asset Logo

Charles River Laboratories

CRL

NYSE
$330.175.47% (+17.15)
$
₹
$330.175.47% (+17.15)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $15.7B the stock is ranked 696

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

354.66
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.91
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.92
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.12
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-5.96%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 17 analysts reports

Buy
14 analysts
Hold
2 analysts
Sell
1 analyst

Price Upside

-2.28%

Earnings Growth

+10.66%

Rev. Growth

-2.45%

See Detailed Forecast

Company Profile

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
37.24
37.24
1Y Return
19.25%
19.25%
Buy Reco %
85.18
85.18
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
34.60
34.60
1Y Return
20.71%
20.71%
Buy Reco %
68.18
68.18
Waters Corporation
WAT
Waters Corporation
P/E Ratio
195.64
195.64
1Y Return
21.8%
21.8%
Buy Reco %
78.26
78.26
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
32.18
32.18
1Y Return
25.54%
25.54%
Buy Reco %
90.00
90.00
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
38.99
38.99
1Y Return
85.02%
85.02%
Buy Reco %
47.61
47.61
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies -2.28% growth, versus a trailing 3-year CAGR of 21.62%.

2026
Current$326.29Baseline
Analyst Target - 1 year
Target$318.87-2.28%

All values in $

202220232024202520262027$214.33$262.53$310.72Target-2.28%
2026
Current$326.29Baseline
Analyst Target - 1 year
Target$318.87-2.28%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -2.45% growth, versus a trailing 3-year CAGR of 0.33%.

2025
Current$4.01Baseline
Forecast for Dec 2026
High$3.95-1.43%
Average$3.91-2.45%
Low$3.90-2.85%

All values in $ Billion

2021202220232024202520263.543.974.124.044.01Low-2.85%Average-2.45%High-1.43%
2025
Current$4.01Baseline
Forecast for Dec 2026
High$3.95-1.43%
Average$3.91-2.45%
Low$3.90-2.85%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

Higher earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 10.66% growth, versus a trailing 3-year CAGR of -2.61%.

2025
Current$10.28Baseline
Forecast for Dec 2026
High$11.49+11.8%
Average$11.38+10.66%
Low$11.02+7.2%

All values in $

20212022202320242025202610.3311.1310.6510.3210.28Low+7.2%Average+10.66%High+11.8%
2025
Current$10.28Baseline
Forecast for Dec 2026
High$11.49+11.8%
Average$11.38+10.66%
Low$11.02+7.2%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.9
-0.2
0.9
-0
1
-0
0.9
0.3
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue1.02110.981.0310.990.9910.98
Net Income0.080.06-0.210.020.050.05-0.27-0.01-00.33
Net Profit Margin8.76%6.80%-21.51%2.58%5.06%5.41%-27.81%-1.49%-0.14%33.89%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Charles River Laboratories 354.665.910.12
Thermo Fisher Scientific Inc37.244.722.02
Agilent Technologies Inc34.606.711.48
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CRL with any stock or ETF
Compare CRL with any stock or ETF
Comparing from
CRL
TMO
A
Loading...

Frequently asked questions

  1. Charles River Laboratories (CRL) share price today is $330.17 as of November 6, 2026 at 8:30 PM IST. The stock touched a day high of $332.81 and a day low of $316.65.

  2. Charles River Laboratories stock trades on NYSE under the ticker symbol CRL.

  3. Charles River Laboratories's market capitalization is $15.71B as of November 6, 2026 at 8:30 PM IST.

  4. Charles River Laboratories's price-to-earnings (P/E) ratio is 354.66 as of November 6, 2026.

  5. Charles River Laboratories's price-to-book (P/B) ratio is 5.91 as of November 6, 2026.

  6. Yes, You can buy Charles River Laboratories shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Charles River Laboratories shares in three steps: 1. Search Charles River Laboratories on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Charles River Laboratories trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Charles River Laboratories (CRL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0302 shares at the current price of $330.17.

Loading...